NEWS: Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax’ Recombinant Nanoparticle #COVID19 Vaccine ir.novavax.com/2021-08-05-Nov… 
The submissions were made to the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.
“Today’s submission of our recombinant nanoparticle COVID-19 vaccine, the first protein-based option filed with any regulatory agency, represents a major milestone in Novavax’ transformation into a commercial global vaccine company,” said Stanley C. Erck, President and CEO
“This important step toward access to millions of doses of a safe and effective vaccine for countries with an urgent need to control the pandemic was made possible through our strategic partnership with @SerumInstIndia, and it demonstrates the power of global collaboration.”
A submission to the @WHO for emergency use listing (EUL) based on the DCGI submission is expected to be filed in August.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
